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Abstract
Background: Although the recreational use of psychoactive substances is common there is only limited systematic
collection of data on acute drug toxicity or hospital presentations. Currently, data from Switzerland are only available
from the University Hospital of Basel. The present study aimed to describe the presentations due to recreational drug
use at an emergency department in Bern, Switzerland during a 4 year period.
Methods: Retrospective analysis of cases presenting from May 2012 to April 2016 at the emergency department of the
University Hospital of Bern, Switzerland, with symptoms/signs consistent with acute toxicity of recreational drug use.
The cases were retrieved using a comprehensive full-text search algorithm of the electronic health records. Isolated
ethanol intoxications were excluded.
Results: During the study period, 503 of the 157,328 emergency department attendances were directly related to
acute toxicity of substances used recreationally. The mean patient age was 33 years (range 16–74), 68% were male.
Alcohol co-ingestion was reported in 54% of the cases, and use of more than one recreational drug in 37% of the
cases. Most presentations were related to cocaine (29%), cannabis (26%), heroin (20%) and benzodiazepines/sedatives
(18%). Urine drug screening immunoassay was available in 277 cases (55%). The most frequently detected substances
were cannabis (29%), cocaine (22%), benzodiazepines (21%) and opioids excluding methadone (20%). There were only
two intoxications with novel psychoactive substances (NPSs): One with methylone and one with 2,5-dimethoxy-4(n)-
propylphenethylamine (2C-P). The majority of patients (58%) displayed impaired consciousness (Glasgow Coma Scale
(GCS) <15) upon presentation and/or pre-hospital; 21% were unconscious (GCS <8). Other frequent symptoms were
agitation (36%), tachycardia (29%), and anxiety (24%). Severe complications included two fatalities, three acute
myocardial infarctions, two intracranial haemorrhages, as well as psychosis and seizures in 71 and 26 cases, respectively.
Conclusions: Most medical problems related to recreational drug use were associated with cocaine and cannabis use
and were mainly characterised by central nervous system depression, sympathomimetic toxicity and/or psychiatric
disorders. Presentations related to acute toxicities of NPSs appear to be uncommon, while prescription drugs were
after classical recreational drugs the substances most commonly reported.
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Background
The recreational use of psychoactive substances is com-
mon. It is estimated that almost a quarter of the adult
population in the European Union have tried illicit drugs
at some point in their lives [1]. The most commonly
used drug in Europe is cannabis, followed by cocaine,
3,4-methylenedioxymethamphetamine (MDMA), and
amphetamines [1]. However, levels of lifetime use differ
considerably between countries [1]. Substance use data
are usually collected on the basis of indicators such as
custom seizures, drug-related deaths, and user surveys.
However, such data often lack information on the acute
toxicities of these substances. Novel psychoactive sub-
stances (NPSs, also known as “designer drugs” and “legal
highs”) are usually analogues or derivatives of controlled
substances produced in order to circumvent regulations
and their use has rapidly increased in recent years [2]. In
2015, 98 NPSs were reported to the European Monitor-
ing Centre for Drugs and Drug Addiction (EMCDDA)
for the first time, bringing the number of NPSs detected
for the first time in the last 5 years to 380 (101 in 2014,
81 in 2013) [1]. The NPSs are typically not detectable
with the usual drug of abuse immunoassays. Thus, they
can cause acute toxicities and medical complications,
including deaths, but escape detection.
There is currently only limited systematic data on acute
drug toxicity causing hospital presentations. Well-
organised monitoring systems for drug-related health
emergencies can expand the limited data currently avail-
able on acute toxicities of recreational substances in
general and on NPSs in particular, thus contributing to the
prevention of medical emergencies and the improvement
of management strategies of acute drug toxicity [3, 4]. Data
from emergency departments (EDs) provide a unique
insight into acute health harms related to drug use and
serve both as drug-trend monitoring and early warning
tool. Important data in this field come from the European
Drug Emergencies Network (Euro-DEN), established in
2013. The project aims to improve knowledge on acute
recreational drug toxicity by collecting data on ED visits
across Europe [3]. First results showed that opioids were
the drugs most frequently associated with acute drug tox-
icity presentations, with heroin being most commonly
involved (24% of the presentations) [5]. Cocaine and
cannabis were also prominent (16% each), while NPSs were
less commonly reported (11% of the presentations). The
most frequent NPSs were cathinones, particularly mephe-
drone. Currently, data from Switzerland are only available
from the University Hospital of Basel [6, 7], where most
medical problems related to recreational drug use were
associated with cocaine and cannabis and mainly included
sympathomimetic toxicity and/or psychiatric disorders.
NPSs were infrequently associated with ED presentations,
with only four cases in a 2-year period.
As there are no data available from other parts of
Switzerland besides Basel [6, 7] and data from only one
region are not representative of the country, the present
study aimed to describe the presentations related to
acute recreational drug toxicity at a large urban ED in
another main city of Switzerland, Bern, over a period of
4 years. Our main objective was to collect systematic
data on the frequency, type and severity of acute medical
problems due to recreational drug use. Furthermore, we
compared our findings with those from Basel and from
other parts of Europe in order to identify possible local
trends and differences.
Methods
This retrospective study was approved by the local ethics
committee (No. 2016–00413). All patients admitted to
the ED at the University Hospital of Bern with acute rec-
reational drug-related problems between May 2012 and
April 2016 were included. The ED of the Inselspital,
University Hospital of Bern, serves as catchment area for
about 2 million people in the Canton of Bern, with about
40,000 emergency visits a year (≥16 years of age) and is
both a primary care facility (walk-in patients) and a
tertiary referral centre for other hospitals in the area.
Cases were retrieved from the ED specific electronic
patient chart database (E.care®) in which all clinical
documentation (e.g., vital signs, laboratory results, notes,
scanned copies handwritten records) is done by physi-
cians and nurses. The search was performed by the IT-
team of the ED using a comprehensive full-text search
algorithm including all parts of the E.care® medical re-
cords. In brief, the automatic search identified all cases
mentioning abuse, intoxication or related terms and a
large number of substance names, including abbrevia-
tions and misspellings. The same sensitive search terms
have been used in previous studies in Basel [6, 7] and
are listed in the Additional file 1. By searching all parts
of the medical records and using a wide spectrum of
search terms we wanted to be sure that all relevant cases
would be captured, even if that meant that a very large
number of false positive cases would have to be reviewed
manually and excluded (e.g., all cases with history of
substance use including tobacco mentioned, even if not
in relation to the presentation). The retrieved cases were
reviewed by three of the authors of the study (two clin-
ical fellows and one senior physician in clinical pharma-
cology and toxicology). A small proportion of not clear
cases was reviewed together with the senior physician,
who had experience in this field from previous studies in
collaboration with Basel and the Euro-DEN project [5–
7]. All cases included were also reviewed by the senior
physician to asure that the same criteria were applied for
all the cases. The charts of all cases were reviewed but
only patients with acute toxicity were included. A
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recreational drug was defined as “a psychoactive com-
pound that was taken for the purpose of recreational ac-
tivities rather than for medical or work purposes or for
self-harm”. The recreational drug(s) associated with the
presentation were identified on the basis of one or a
combination of the following: the patient’s self-reported
use, information retrieved from witnesses, the opinion of
the physician assessing the patient, and/or analytical re-
sults. Cases lacking substance self-report (e.g., because
of coma, unwillingness to cooperate, language barriers),
but with symptoms and/or analytical test typical of acute
recreational drug toxicity were also included. Data
abstracting was performed in a standardised manner [3,
5–7]. Exclusion criteria were: isolated ethanol intoxica-
tion, drug withdrawal and complications of chronic drug
use (e.g., infected injection sites). Manifestations of drug
withdrawal, although clinically relevant and in some
cases potentially also life-threatening, were excluded as
the main objective of the study was to investigate med-
ical problems in relation to acute toxicity of psychoactive
substances, which can differ greatly from the symptoms
and management of withdrawal. Patients attending the
ED requiring treatment because of symptoms and signs
consistent with an alternate medical diagnosis and not
primarily related to acute recreational drug toxicity (e.g.,
injury related presentation without signs of intoxication
and subsequently found that the patient had used recre-
ational drugs) were also excluded, as the presenting
complaint was not related to the drug use, unless the
trauma was directly related to drug use, e.g., as a result
of hallucinations. The patient demographics (age, sex,
hour and week day of ED visits), the substances used as
reported by the patient or witnesses, the clinical effects,
and clinical outcome were recorded. Clinical variables
included the Glasgow Coma Scale (GCS) score, heart
rate, blood pressure, respiratory rate, body temperature,
laboratory tests and electrocardiography (ECG) findings.
Hyperthermia was defined as a temperature ≥ 39 °C,
measured by any method, hypothermia as a temperature
< 35 °C, hypertension as systolic blood pressure ≥
180 mmHg, hypotension as systolic blood pressure ≤
90 mmHg. Hallucinations were defined as any deceptive
or altered perception (visual, auditory, tactile, olfactory
and/or gustatory), psychosis as any episode of delusions
accompanied by confusion, hallucinations and lack of
insight, seizures as any type of generalised tonic-clonic,
myoclonic, partial or focal seizure. The severity of poi-
soning was assessed using the Poison Severity Score [8].
Minor toxicity refers to mild, transient and spontan-
eously resolving symptoms, moderate toxicity to
pronounced or prolonged symptoms, and severe toxicity
to severe or life-threatening symptoms. A urine drug
screening test using an immunoassay (Triage® TOX
Drug Screen, Alere, Cologne, Germany) was used to
screen for amphetamines, barbiturates, benzodiazepines,
cocaine, methadone, methamphetamines (including
MDMA), opiates, phencyclidine (PCP), tricyclic antide-
pressants, and tetrahydrocannabinol (cannabis). The
cut-off level was 1000 ng/mL for amphetamines, meth-
amphetamines, and tricyclic antidepressants, 300 ng/mL
for barbiturates, benzodiazepines, cocaine, methadone,
and opiates, 50 ng/mL for cannabis, and 25 ng/mL for
PCP [9]. In one case with suspected NPS use an
additional liquid chromatography-mass spectrometry
method was used. Ethanol blood levels were estimated
from osmolar gap using the following equations: serum
ethanol (g/L) = (serum osmolality - (2 * sodium (mEq/L)
+ glucose (mmol/L) + blood urea nitrogen (mmol/L))/
(1.25 * 21.71) and ethanol concentration (g/kg) = serum
ethanol (g/L)/ (1.236) ‰ [10, 11].
Results
Over the 4 year study period, from May 2012 to April
2016, there were 157,328 ED attendances. Among these,
73′258 were identified using the search algorithm as
potential cases. However, most cases were excluded as
the presentation was not related to acute drug toxicity.
After applying the inclusion and exclusion criteria, 503
cases related to acute toxicity of substances used recre-
ationally were detected in 408 different patients. Forty-
five patients presented more than once to the ED due to
symptoms/signs related to acute substance toxicity (27
patients twice, nine patients three times, five patients
four times, one patient five times, two patients nine
times, and one patient 16 times). The mean patient age
was 33 years (range 16–74), and 68% were brought to
the ED by ambulance. The patient characteristics are
shown in Table 1.
The most commonly self-reported recreational drugs
were cocaine (29%), cannabis (26%), heroin (20%) and
benzodiazepines/sedatives (18%) (Fig. 1).
After exclusion of opioids and benzodiazepines, the
most common recreationally used prescription drugs
were methylphenidate (3%), antipsychotics (1%), dextro-
methorphan (1%), monoamine oxidase (MAO) inhibitors
(1%), other antidepressants (1%), and antihistamines
(0.6%). Substances classified as “other” included caffeine,
“thai pills” (2 cases each), inhalation of methanol, non-
steroidal anti-inflammatory drugs (NSAIDs), melanin,
pseudoephedrine, kamagra, propofol, “smileys”, and
“stimulants” not further specified (1 case each). Three
percent of the patients reported that they had used a
substance without knowing what it was, in 9% of the
cases no information was available on the substances
taken, and 3% denied having used any drugs. These
patients were included because they were judged by the
assessing physician as being acutely intoxicated, on the
basis of the symptoms and/or analytical results.
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There were only two cases of NPSs: one with 3,4-methy-
lenedioxymethylcathinone, a cathinone also known as
methylone, and one with 2,5-dimethoxy-4(n)-propylphe-
nethylamine (2C-P) sold as 2,5-dimethoxy-4-bromophe-
nethylamine (2C-B) [12], both of moderate severity. The
characteristics of those cases are shown in Table 2.
Overall, a drug screening was available in 277 cases
(55%). The most frequently detected substances were
cannabis (29%), cocaine (22%), benzodiazepines (21%)
and opiates excluding methadone (20%) (Fig. 2).
Alcohol co-use was analytically confirmed in 35% of
the cases. Among the 175 cases with a positive ethanol
test, the median alcohol concentration was 1.4‰ (range
0.01–4.7).
Table 3 summarises the medical problems.
Among all 503 cases, 21% presented with severe
intoxication (Table 4) and there were two fatalities: a
39-year old female patient with cerebral hypoxia after
intake of approximately 180 mg methadone from the
substitution medication of her partner, and a 33-year old
male patient with cerebral infarction and analytical
detection of cocaine and cannabis (no self-report avail-
able (GCS 5 pre-hospital, intubated at presentation),
diagnosed as possible cardioembolic complication in the
context of cocaine use).
Severe complications included 3 acute myocardial
infarctions (following cocaine use by a 45-year old male
patient, cannabis use by a 52-year old male patient, and
gamma-hydroxybutyrate (GHB) and kamagra use by a
50-year old male patient), 2 intracranial haemorrhages
(43-year and 48-year old male patients, cocaine self-
reported in one case and in the other case analytically
detected together with cannabis and opiates), as well as
psychosis and seizures in 71 and 26 cases, respectively
(Table 3). The outcome data are shown in Table 4. In
374 cases (74%) medical treatment including oxygen and
intravenous fluid administration was provided. Tracheal
intubation was performed in 16 cases (3%). Sedating
drugs (i.e., benzodiazepines and/or antipsychotics) were
administered in 128 cases (25%), an antidote (i.e., nalox-
one, flumazenil, activated charcoal and/or biperiden)
was given in 54 cases (11%).
Discussion
The present study described the presentations related to
acute recreational drug toxicity at a large urban ED in
Bern, Switzerland. Over a period of four years (May
2012 - April 2016), most presentations due to acute rec-
reational drug toxicity were associated with cocaine and
cannabis use. Those were also the substances most com-
monly analytically detected. Only 2 presentations were
related to acute toxicity of NPSs. The typical patient was
young and male, and alcohol had been co-ingested in
the majority of the cases. There were two fatalities and
further severe complications, such as myocardial infarc-
tion and intracranial haemorrhage, while approximately
one fifth of the cases were unconscious at presentation
or prior to hospital admission. However, most intoxica-
tions were of moderate severity and most patients were
discharged home directly from the ED.
Comparing our findings with the similar studies from
Basel [6, 7], another city in Switzerland with an Univer-
sity Hospital and a large urban ED, in both centres
cannabis and cocaine seem to be the leading substances
resulting in ED presentations due to acute toxicity, pos-
sibly indicating a general trend across the country. In
the European data, cocaine and cannabis were also
among the most commonly reported substances (num-
ber 2 and 3, respectively), but the most commonly
reported drug was heroin [5]. Possible reasons for such
differences could be local trends, the well-established
heroin substitution programs in Switzerland, and price
differences of substances among countries. In all studies,
Table 1 Patient characteristics
Number of cases, N = 503 (%)
Male 344 (68)
Female 159 (32)
Age (years)
16–20 67 (13)
21–30 169 (34)
31–40 136 (27)
41–50 89 (18)
> 50 42 (8)
Time of presentation
Night arrival (20:00 – 8:00 h) 254 (50)
Weekend arrival (Friday 17:00 h -
Monday 8:00 h)
233 (46)
Ethanol co-ingestion (self-reported)
Yes 274 (54)
No 46 (9)
Not known 183 (36)
Drug use reported
1 substance 260 (52)
> 1 substances 187 (37)
No drug use reported 13 (3)
No information available (e.g., coma,
uncooperative)
43 (9)
Drug use analytical results
1 substance 74 (15)
> 1 substances 178 (35)
Negative test (absence or insufficient
test sensitivity)
25 (5)
No drug test performed 226 (45)
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the typical patient presenting to the ED due to acute
toxicity of recreational substances was male, in his early
thirties, and was usually brought to the ED by ambu-
lance overnight after using a classical recreational
substance, often in combination with alcohol [5–7].
Another interesting similarity among the studies men-
tioned is that - despite the dramatic increase in the
number of NPSs detected in recent years - presentations
related to NPSs were much less common than those
related to classical recreational drugs. This may indicate
that NPSs possess less acute toxicity than classical recre-
ational substances, that NPSs are consumed to a lesser
extent or may be due to the fact that they escape detec-
tion with the normal immunoassay in many cases, espe-
cially if the patient does not report or is unaware of
their use (e.g., if they are sold under other names, or in
combination with other substances). One such example
in the present study was the 2C-P case (detected by
using liquid chromatography-mass spectrometry, usual
doses 6–10 mg), which was mistaken for the better-
known, less potent and shorter-acting 2C-B (usual doses
10–20 mg), and thus led to more severe and prolonged
intoxication after intake of approximately 25 mg [12].
The 2C drugs are a subgroup of phenethylamines with
primarily hallucinogenic properties [13]. Different
ligands at position 4 on the phenyl ring within this fam-
ily (e.g., bromine in 2C-B or propyl in 2C-P) can lead to
great differences in receptor affinity [14]. The second
NPS reported in our study was the synthetic cathinone
3,4-methylenedioxymethylcathinone (methylone or βk-
MDMA) [15]. In this case, the patient reported buying
the substance from Beijing, where it was still legal. The
Fig. 1 Reported substance use (count of cases)
Table 2 NPS cases characteristics
NPS self-
reported
Age/ gender NPS dose
self-reported
Co-ingestion alcohol Clinical presentation Treatment Tox. laboratory
analysis
Outcome
Methylone 32/ female 1 - 1.5 g cumulative
during 6.5 h
yes Palpitations, fear,
agitation, sweating,
tremor, vertigo,
paraesthesias, muscle
twitching, vomiting
1 mg sublingual
lorazepam
10 mg i.v.
metoclopramide
intravenous fluid
administration
Negative
(immunoassay)
Discharged
home the
same day
2C-B 19/ male 25 mg yes Severe hallucinations,
mydriasis, tachycardia,
agitation, confusion
benzodiazepines
4 mg i.v.
haloperidol
2C-P (liquid
chromatography-
mass spectrometry)
Discharged
home 11 h
later
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immunoassay drug screening was negative, as this test
cannot detect most NPSs, so no NPS would have been
registered without self-report. Methylone is a first gener-
ation synthetic substance from the group of the cathi-
nones [16], which are derivatives of the naturally
occurring beta-ketone amphetamine analogue found in
the leaves of the Catha edulis plant [17]. Methylone, the
beta-ketone analogue of MDMA, emerged in the recre-
ational drug market in the mid-2000’s under the brand
name “Explosion” and was the first of these substances
to be marketed via the Internet and at smart shops [16].
Desired effects range from amphetamine-like stimulation
(e.g., increased energy, alertness) to entactogenic effects
similar to those produced by MDMA (e.g., empathy,
openness) [15]. In accordance with the symptoms
reported by the patient in our study, the most common
adverse effects include palpitations, vomiting, anxiety,
sweating, unsteadiness of the hands, but also seizures,
hyperthermia, psychosis, hallucinations and suicidal
ideation [15]. Fatalities have also been reported [18–20].
Common oral doses (the most popular route of adminis-
tration) are 100–300 mg, and doses higher than 250 mg
are considered as “heavy” consumption [16]. The total
dose reported by our patient (1–1.5 g) is thus very high.
However, it is possible that the patient used a larger dose
as “boosting” first, followed by smaller doses (“bumps”)
to maintain the desired effects [15].
Beside the use of classical recreational drugs and
NPSs, a further issue of increasing concern is the recre-
ational use of prescription drugs. Among the ten cases
of reported recreational methadone use in our study,
seven were in a methadone substitution program, and in
one of the fatal cases the patient used the methadone of
her partner who was under maintenance therapy. Such
cases demonstrate some of the risks related to long-term
opioid maintenance treatment and the importance of the
adjunctive psychosocial care of these patients. Sedatives
and hypnotics are after opioids the most commonly mis-
used prescription drugs in Europe [21]. Accordingly,
benzodiazepines were the more commonly self-reported
substances after cocaine, cannabis and heroin in our
study. According to surveys, the main reasons for their
use were to help sleep, to cope with stress, and/or to
“get high” and almost 15% of the participants misusing
them reported doing so at least once weekly [22].
Although the abuse and misuse potential of many of the
other self-reported recreationally used prescription drugs
in our study is known and plausible on the basis of their
mechanism of action (e.g., psychostimulant effect of
methylphenidate and modafinil, dissociative effect of
N-methyl-D-aspartate (NMDA) receptor antagonists
such as ketamine and dextromethorphan, sedative effect
of antihistamines), this is not always the case for other
substance groups, e.g., antidepressants. Antidepressants
include a variety of substances with different pharmaco-
logical properties (e.g., sedation, stimulation), some of
which make abuse attractive [23]. For example, bupro-
pion, the most commonly misused antidepressant of the
last decade [23], acts by inhibiting norepinephrine and
dopamine reuptake [24], similarly to other indirect
sympathomimetics (e.g., cocaine). In our study, recre-
ational bupropion was administered intravenously in one
case (approximately 1500 mg i.v.) and was intended to
cause an amphetamine-like effect. Intravenous abuse of
bupropion is also found in case reports and the drug can
be acquired relative easily by expressing the wish to quit
smoking [25]. Another category of antidepressants com-
monly misused are MAO inhibitors, which prevent the
breakdown of monoamine neurotransmitters by MAO-A
and/or MAO-B [23]. In our study, MAO inhibitor use
was reported in six cases by the same patient, who
presented a total of 16 times to the ED due to acute
recreational substance use toxicity. The patient used the
MAO inhibitor in combination with phenethylamine in
Fig. 2 Substances analytically detected (count of cases)
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five of the cases, most probably as an attempt to
decrease its breakdown and thus potentiate its effects.
Phenethylamine, also known as β-phenylethylamine,
enhances catecholamine release, and can be obtained
legally as dietary supplement. Unlike its derivatives (e.g.,
amphetamine), it is rapidly metabolised primarily by
MAO-B, thus normally preventing significant concentra-
tions from reaching the brain [26, 27]. Recreational use
of methylphenidate was reported in 15 cases in our
study by 12 different patients (one patient presented four
times). An increase in reports of non-medical use of
methylphenidate in recent years has been shown in a
retrospective analysis from the Swiss Toxicological Infor-
mation Centre [28]. In that study, the most common
route of application was oral, but nasal and intravenous
administration route was used in a substantial propor-
tion of the cases, and 40% of the abusers reportedly used
methylphenidate as a prescription drug for ADHD. Simi-
lar to those findings, half of the patients in our study (6
out of 12) received methylphenidate as treatment for
their ADHD, but used it differently than prescribed
(higher doses and/or other route of administration), and
one patient took the drug from his girlfriend who had
an ADHD diagnosis. In our study, the reported adminis-
tration route was oral in the majority of the cases (9/15),
i.v. and nasal administration were reported in 2 and 1
case(s), respectively, while in 3 cases the route of admin-
istration was not specified. Methylphenidate was also
the most commonly reported prescription drug used for
neuroenhancement (e.g., nonmedical use of a substance
to improve cognitive function) in surveys among Swiss
university students [29] and Swiss secondary school
students [30].
As main limitations of the study, there were some missing
data (the initial patient data were not recorded in a standar-
dised manner), some symptoms described could have been
related to substance withdrawal and not acute toxicity (e.g.,
seizures associated with benzodiazepine or alcohol with-
drawal) or to aetiologies other than the acute toxicity of the
psychoactive substances studied (e.g., vomiting because of
alcohol co-ingestion or gastroenteritis, pre-existing psychi-
atric pathologies not recognised or documented as such).
Because of the co-use of alcohol leading to impaired con-
sciousness in many cases, severe intoxications may have
been overrepresented. Furthermore, substances taken as
Table 3 Clinical characteristics of acute recreational drug
intoxications
Number of cases, N = 503 (%)
Cardiovascular
Chest pain 34 (7)
Palpitations 41 (8)
Dyspnea 25 (5)
Hypertension (systolic blood
pressure ≥180 mmHg)
14 (3)
Hypotension (systolic blood
pressure ≤90 mmHg)
18 (4)
Tachycardia (>100 beats
per minute)
144 (29)
Myocardial infarction 3 (<1)
Arrhythmias 5 (1)
Psychiatric
Anxiety, nervousness, and/
or fear
121 (24)
Psychosis 71 (14)
Hallucinations 54 (11)
Agitation and/or aggression 179 (36)
Panic attack 7 (1)
Insomnia 18 (4)
Suicidal ideation 14 (3)
Neurological
Loss of consciousness (GCS < 8)
on presentation or pre-hospital
107 (21)
Impaired consciousness (GCS <15)
on presentation or pre-hospital
291 (58)
Vertigo and/or dizziness 39 (8)
Headache 24 (5)
Paraesthesias 17 (3)
Seizure 26 (5)
Tremor 22 (4)
Amnesia 33 (7)
Other neurological symptoms 36 (7)
Miosis 87 (17)
Mydriasis 74 (15)
Respiratory depression 69 (14)
Intracranial haemorrhage 2 (<1)
Miscellaneous
Hyperventilation 22 (4)
Nausea and/or vomiting 61 (12)
Sweating 19 (4)
Malaise 13 (3)
Abdominal pain 14 (3)
Hyperthermia (≥39.0 °C) 3 (<1)
Hypothermia (<35.0 °C) 10 (2)
Table 3 Clinical characteristics of acute recreational drug
intoxications (Continued)
Muscle cramps 20 (4)
Injuries (e.g., fracture, wound) 23 (5)
Acute kidney injury 2 (<1)
Elevated creatine kinase (>250 U/L) 71 (14)
Weakness, walking impairment 20 (4)
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medication (e.g., benzodiazepines, methadone, antidepres-
sants) or given by the paramedics (e.g., benzodiazepines)
could have been overrepresented in the analytical results;
this also applies to substances that can be detected in urine
samples beyond the time period of acute intoxication (e.g.,
cannabis). On the other hand, substances which can be
detected only during a very short time period (e.g., GHB) or
cannot be detected with the immunoassay test used in the
study (e.g., LSD, NPSs) may have gone undetected if their
use was not reported. Additionally, some patients with
psychiatric symptoms were transferred to a psychiatric ward
shortly after arrival at the ED, thus not allowing full docu-
mentation of treatment and outcome. Moreover, data from
only one ED may reflect local trends and may not be
representative.
The strengths of our study include the sensitive search
algorithm used and the detailed documentation, in con-
trast to studies based on coded diagnoses only, which
would have led to missing relevant cases with substance
use not mentioned as a diagnosis, or studies based on
laboratory data only, which would have caused the inclu-
sion of not clinically relevant cases (e.g., cannabis detec-
tion long after acute intoxication). Further strengths
include the drug screening performed in most cases, the
relatively long time period studied, and the collection and
analysis of data in a systematic manner, which allowed a
comparison with the similar data from other cities in
Switzerland (i.e., Basel) and elsewhere in Europe.
Conclusion
In conclusion, this retrospective study at a large urban
ED in Bern, Switzerland over a period of 4 years showed
that most presentations due to acute recreational drug
toxicity were associated with cocaine and cannabis use
and were mainly characterised by central nervous system
depression, sympathomimetic toxicity and/or psychiatric
disorders. Those results are in accordance with the-
currently only limited- data available from other parts of
Switzerland (Basel), thus potentially indicating national
trends. Beside classical recreational drugs, the substances
most commonly reported in this study were prescription
drugs, whereas ED presentations related to acute toxic-
ities of NPSs appear to be uncommon, either because
NPSs are not commonly used, or because their use leads
to ED presentations less often. Future research from
other parts of Switzerland, but also Europe, could pro-
vide more evidence to help distinguish between these
two hypotheses. Furthermore, the data of this study can
contribute to the recognition of prescription drug abuse
potential and to the development of preventive strategies
such as clinician training to ensure appropriate prescrip-
tion, and regulation of substances with abuse potential.
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Table 4 Severity of poisoning and outcome
Number of cases, N = 503 (%)
Severity of poisoning
Minor 177 (35)
Moderate 220 (44)
Severe 104 (21)
Fatal 2 (<1)
Outcome
Medically discharged home 299 (59)
Self-discharged 42 (8)
Admission to critical care unit 32 (6)
Admission to ward other than critical
care unit
19 (4)
Admission to psychiatric clinic 111 (22)
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